- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
- Media
- Partners
- Contact Us
Press Releases
Sep
- Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
- Dr. Reddy's launches Minoxidil for women following first-ever approval in India for the treatment of female pattern hair loss
- Dr. Reddy's Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
- Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
Aug
- Dr. Reddy's Laboratories announces the launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market
- Dr. Reddy's announces the re-launch of over-the-counter Naproxen Sodium Tablets USP, 220 mg, store-brand equivalent of Aleve® in the U.S. Market
- Press Release - Dr. Reddy's-BDSI ELYXYB (celecoxib oral solution) 25 mgmL (002)
Jun
May
- Dr. Reddy’s Q4 & FY21 Financial Results
- Dr. Reddy’s Laboratories Announces Launch of the Sputnik V vaccine in the Indian Market
- Dr. Reddy's Laboratories announces the launch of Ertapenem for Injection in the U.S. Market
- Dr. Reddy's Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Apr
- Dr. Reddy's Laboratories announces the launch of Albendazole Tablets, USP in the U.S. Market
- Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
- Dr. Reddy's Laboratories announces the launch of a generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market
Feb
- Dr. Reddy’s Recalls Prescription Drug Blister Packages Due to Risk of Poisoning
- Dr. Reddy's Laboratories announces the launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
- Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V
- Dr. Reddy's Laboratories announces the launch of Capecitabine Tablets, USP in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Vigabatrin Tablets, USP in the U.S. Market
- Dr Reddy’s is pleased to share that Sputnik V showed strong efficacy, immunogenicity and safety results in the Interim Phase-3 data on 19866 people in the clinical trial conducted by its partner, RDIF
Jan
- Dr. Reddy’s Q3 & 9M FY21 Financial Results
- Dr. Reddy’s and GRA announce Avigan Pivotal Studies Update Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America
- Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India
- Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India
- Dr. Reddy's Laboratories to present at the 39th Annual J.P. Morgan Healthcare Conference
- Dr. Reddy's Laboratories announces the launch of Febuxostat Tablets in the U.S. Market
